Posts Tagged ‘immunotherapy’

Cells…in a box

Author: Guest, 02/13/17

Heather Blumenthal has been writing about health and health research for more than 20 years and never loses her fascination with the advances Canadian researchers are making. You can reach her at hblumenthal@sympatico.ca It’s like magic – insert a cancer patient’s blood cells in one end and out the other end come T-cells adapted for…Read more

Learning About Industry from the Insiders at Phacilitate Cell and Gene Therapy World 2017

Author: Nicole Forgione, 02/08/17

In January, I attended Phacilitate’s Cell and Gene Therapy World in Miami, Florida. At this meeting industry leaders from around the world gather to discuss manufacturing, regulation and adoption of cell and gene therapies (C&GT). This was my first industry-focused conference, and it was a great chance to learn the ropes from experienced players in…Read more

Sculpted to a T: Synthetic T-cells for a more controlled immune response

Author: Holly Wobma, 10/18/16

I have a confession.  This is not a blog about stem cells. It is, however, a blog about cells with infinite possibilities of fate. Because we are entering the world of synthetic biology, where crafty cellular engineering has enabled a new level of control over immune cell function. This work comes out of Wendell Lim’s…Read more

Cell Therapy Deal Review: March

Author: Mark Curtis, 04/25/16

Welcome to your Cell Therapy Deal Review for the month of March. Cellectis continues to differentiate through a collaboration with MabQuest. PCT formed a partnership with Japanese conglomerate Hitachi. Kite partnered with Roche’s Genentech on a program for lymphoma. Cellectis (CLLS) has already separated itself from the pack with UCART19, a universal CAR product targeting…Read more

Update from the Clinic: February

Author: Mark Curtis, 03/24/16

Welcome to your Update from the Clinic for the month of February. bluebird made its debut in the oncology market and treated its first patient with a chimeric antigen receptor (CAR) product targeting a novel antigen. Ziopharm enrolled its first patient in a study investigating a non-viral CD19 CAR product, while Sangamo entered the clinic…Read more

Cell Therapy Deal Review: February

Author: Mark Curtis, 03/15/16

Welcome to your deal review for the month of February. Astellas tied-off its acquisition of Ocata while GSK and Adaptimmune expanded their collaboration to develop cell-based immunotherapies. AVROBIO, a new cell and gene company based in Boston, Mass, and Toronto, Ontario, launched with programs in leukemia in Fabry disease. After a drawn out process, Astellas…Read more

Update from the Clinic: August

Author: Mark Curtis, 09/29/15

. Welcome to your Update from the Clinic for the month of August. The adult stem cell community enjoyed a much needed confidence boost after TiGenix announced its Phase 3 trial hit its primary endpoint. Northwest confirmed its Phase 3 trial of DCVax in glioblastoma is still underway despite rumours that the trial had been…Read more

Lessons from Dendreon

Author: Mark Curtis, 11/20/14

. You have all by now heard that Dendreon has filed for bankruptcy protection. If you’re a regular reader of Signals, you may have first heard the news here. While the company has successfully reached agreements on a financial restructuring with a majority of its senior debt holders, its fate remains unclear and could include…Read more

If cell therapy isn’t about the cells or the therapy, what is it about?

Author: David Brindley, 11/19/14

. With contributions from James Smith, a recent Oxford University graduate and current CASMI Translational Stem Cell Consortium Research Associate.   Both the IBC Cell Therapy Bioprocessing (ICTB) conference and the Stem Cells and Regenerative Medicine Congress (SCRMC) took place recently. The conferences shared several common themes: one being the presence of a significant focus…Read more

Update from the Clinic: September

Author: Mark Curtis, 10/14/14

. Welcome to your Update from the Clinic for the month of September. There’s a mixture of news from the cancer stem cell companies and immunotherapy companies this past month. Amongst other things, the FDA removed the previously imposed partial hold on one of OncoMed’s therapeutics; Opexa Therapeutics announced its next therapeutic program; and, Harvard…Read more